8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 2, 2026·SEC
Material company update
Mar 30, 2026·SEC
Ultragenyx Pharmaceutical Inc.(RARE)Earnings, Financials & Key Ratios
RARE•NASDAQ
$25.93
$2.55B mkt cap·Price updated May 6, 2026
AboutUltragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.Show more
- Revenue$673M+20.1%
- EBITDA-$500M
- Net Income-$575M-1.0%
- EPS (Diluted)-5.83+7.3%
- Gross Margin83.8%-2.9%
- EBITDA Margin-74.29%+16.8%
- Operating Margin-79.49%+16.9%
- Net Margin-85.44%+15.9%
- ROE-607.51%-187.0%
- ROIC-89.37%+74.0%
- Interest Coverage-8.63-7.8%
RARE Key Insights
Ultragenyx Pharmaceutical Inc. (RARE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 19.9%
✗Weaknesses
- ✗Profits declining 25.2% over 5 years
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
RARE Price & Volume
Ultragenyx Pharmaceutical Inc. (RARE) stock price & volume — 10-year historical chart
Loading chart...
RARE Growth Metrics
Ultragenyx Pharmaceutical Inc. (RARE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years19.95%
3 Years22.81%
TTM13.33%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-10.88%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-3.91%
Return on Capital
10 Years-48.07%
5 Years-42.58%
3 Years-45.75%
Last Year-46.37%
RARE Recent Earnings
Ultragenyx Pharmaceutical Inc. (RARE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 5, 2026EPS
$1.84
Est $1.50
-22.9%
Revenue
$136M
Est $158M
-14.1%
Q1 2026
Feb 12, 2026EPS
$1.29
Est $1.20
-7.5%
Revenue
$207M
Est $199M
+4.2%
Q4 2025
Nov 4, 2025EPS
$1.81
Est $1.23
-47.2%
Revenue
$160M
Est $200M
-19.9%
Q3 2025
Aug 5, 2025EPS
$1.17
Est $1.27
+7.9%
Revenue
$166M
Est $166M
+0.3%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $1.84vs $1.50-22.9% | $136Mvs $158M-14.1% |
| Q1 2026 | Feb 12, 2026 | $1.29vs $1.20-7.5% | $207Mvs $199M+4.2% |
| Q4 2025 | Nov 4, 2025 | $1.81vs $1.23-47.2% | $160Mvs $200M-19.9% |
| Q3 2025 | Aug 5, 2025 | $1.17vs $1.27+7.9% | $166Mvs $166M+0.3% |
Based on last 12 quarters of dataView full earnings history →
RARE Peer Comparison
Ultragenyx Pharmaceutical Inc. (RARE) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BMRN | 10.5B | 54.60 | 30.33 | 12.87% | 8.29% | 4.41% | 0.11 | |
 SRPT | 2.42B | 23.03 | -3.23 | 15.58% | 2.98% | 4.89% | 0.91 | |
 IONS | 12.7B | 76.85 | -32.29 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 KRYS | 8.52B | 288.90 | 42.24 | 33.94% | 53.92% | 19.25% | 0.01 | |
 RYTM | 6.6B | 96.61 | -31.06 | 45.83% | -93.84% | -204.35% | 1.77 | |
 LGND | 4.57B | 232.55 | -1057.05 | 27.28% | 19.34% | 5.11% | 0.01 |
Compare RARE vs Peers
Ultragenyx Pharmaceutical Inc. (RARE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RARE Income Statement
Ultragenyx Pharmaceutical Inc. (RARE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 2.61M | 51.49M | 103.71M | 271.03M | 351.41M | 363.33M | 434.25M | 560.23M | 673M | 669.43M |
| Revenue Growth % | 1863.91% | 1871.48% | 101.41% | 161.32% | 29.66% | 3.39% | 19.52% | 29.01% | 20.13% | 13.33% |
| Cost of Goods Sold | 1K | 1.15M | 9.01M | 6.13M | 16.01M | 28.32M | 45.21M | 76.73M | 109M | 109.99M |
| COGS % of Revenue | 0.04% | 2.23% | 8.69% | 2.26% | 4.56% | 7.79% | 10.41% | 13.7% | 16.2% | - |
| Gross Profit | 2.61M▲ 0% | 50.35M▲ 1828.3% | 94.71M▲ 88.1% | 264.9M▲ 179.7% | 335.4M▲ 26.6% | 335.01M▼ 0.1% | 389.04M▲ 16.1% | 483.5M▲ 24.3% | 564M▲ 16.6% | 559.44M▲ 0% |
| Gross Margin % | 99.96% | 97.77% | 91.31% | 97.74% | 95.44% | 92.21% | 89.59% | 86.3% | 83.8% | 83.57% |
| Gross Profit Growth % | 101.43% | 1828.34% | 88.1% | 179.71% | 26.61% | -0.12% | 16.13% | 24.28% | 16.65% | - |
| Operating Expenses | 331.55M | 421.72M | 518.88M | 595.02M | 717.13M | 983.93M | 958.25M | 1.02B | 1.1B | 1.12B |
| OpEx % of Revenue | 12693.45% | 818.96% | 500.3% | 219.54% | 204.08% | 270.81% | 220.67% | 181.97% | 163.3% | - |
| Selling, General & Admin | 99.91M | 127.72M | 161.52M | 182.93M | 219.98M | 278.14M | 309.8M | 321.61M | 349M | 350.27M |
| SG&A % of Revenue | 3825% | 248.03% | 155.74% | 67.5% | 62.6% | 76.55% | 71.34% | 57.41% | 51.86% | - |
| Research & Development | 231.64M | 294M | 357.36M | 412.08M | 497.15M | 705.79M | 648.45M | 697.87M | 750M | 770.95M |
| R&D % of Revenue | 8868.45% | 570.93% | 344.56% | 152.04% | 141.48% | 194.26% | 149.33% | 124.57% | 111.44% | - |
| Other Operating Expenses | 0 | 3.95M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -328.94M▲ 0% | -371.37M▼ 12.9% | -424.17M▼ 14.2% | -330.12M▲ 22.2% | -381.74M▼ 15.6% | -648.92M▼ 70.0% | -569.21M▲ 12.3% | -535.97M▲ 5.8% | -535M▲ 0.2% | -561.78M▲ 0% |
| Operating Margin % | -12593.49% | -721.18% | -408.98% | -121.8% | -108.63% | -178.6% | -131.08% | -95.67% | -79.49% | -83.92% |
| Operating Income Growth % | -32.63% | -12.9% | -14.22% | 22.17% | -15.64% | -69.99% | 12.28% | 5.84% | 0.18% | - |
| EBITDA | -323.12M | -351.83M | -415.63M | -317.86M | -368.5M | -630.7M | -543.2M | -500.43M | -500M | -535.77M |
| EBITDA Margin % | -12370.48% | -683.24% | -400.75% | -117.28% | -104.86% | -173.59% | -125.09% | -89.33% | -74.29% | -80.03% |
| EBITDA Growth % | -32.11% | -8.89% | -18.13% | 23.53% | -15.93% | -71.15% | 13.87% | 7.87% | 0.09% | -12.11% |
| D&A (Non-Cash Add-back) | 5.83M | 19.54M | 8.54M | 12.26M | 13.24M | 18.22M | 26.01M | 35.54M | 35M | 26.01M |
| EBIT | -318.34M | -197.1M | -398.31M | -152.07M | -423.56M | -658.71M | -542.46M | -504.55M | -535M | -379.36M |
| Net Interest Income | 4.07M | 9.54M | 12.1M | -26.25M | -27.49M | -31.94M | -39.32M | -26.54M | -37M | -29.02M |
| Interest Income | 4.07M | 9.54M | 13.24M | 7.04M | 1.93M | 11.07M | 26.69M | 36.51M | 25M | 24.17M |
| Interest Expense | 0 | 0 | 1.14M | 33.29M | 29.42M | 43.02M | 66M | 63.04M | 62M | 26.19M |
| Other Income/Expense | 10.6M | 174.28M | 24.73M | 144.76M | -71.24M | -52.81M | -39.26M | -31.61M | -36M | -43.77M |
| Pretax Income | -318.34M▲ 0% | -197.1M▲ 38.1% | -399.44M▼ 102.7% | -185.36M▲ 53.6% | -452.98M▼ 144.4% | -701.73M▼ 54.9% | -608.46M▲ 13.3% | -567.59M▲ 6.7% | -571M▼ 0.6% | -605.54M▲ 0% |
| Pretax Margin % | -12187.52% | -382.75% | -385.14% | -68.39% | -128.91% | -193.14% | -140.12% | -101.31% | -84.84% | -90.46% |
| Income Tax | -16.2M | 514K | 3.28M | 1.21M | 1.04M | 5.7M | -1.82M | 1.6M | 4M | 1.82M |
| Effective Tax Rate % | 5.09% | -0.26% | -0.82% | -0.65% | -0.23% | -0.81% | 0.3% | -0.28% | -0.7% | -0.3% |
| Net Income | -302.14M▲ 0% | -197.61M▲ 34.6% | -402.73M▼ 103.8% | -186.57M▲ 53.7% | -454.02M▼ 143.4% | -707.42M▼ 55.8% | -606.64M▲ 14.2% | -569.18M▲ 6.2% | -575M▼ 1.0% | -609.36M▲ 0% |
| Net Margin % | -11567.34% | -383.75% | -388.31% | -68.84% | -129.2% | -194.71% | -139.7% | -101.6% | -85.44% | -91.03% |
| Net Income Growth % | -22.88% | 34.6% | -103.8% | 53.67% | -143.36% | -55.81% | 14.25% | 6.17% | -1.02% | -10.88% |
| Net Income (Continuing) | -302.14M | -197.61M | -402.73M | -186.57M | -454.02M | -707.42M | -606.64M | -569.18M | -575M | -609.36M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7M | 7M | 7M |
| EPS (Diluted) | -7.12▲ 0% | -3.97▲ 44.2% | -7.12▼ 79.3% | -3.07▲ 56.9% | -6.70▼ 118.2% | -10.12▼ 51.0% | -8.25▲ 18.5% | -6.29▲ 23.8% | -5.83▲ 7.3% | -6.06▲ 0% |
| EPS Growth % | -14.65% | 44.24% | -79.35% | 56.88% | -118.24% | -51.04% | 18.48% | 23.76% | 7.31% | -3.91% |
| EPS (Basic) | -7.12 | -3.97 | -7.12 | -3.07 | -6.70 | -10.12 | -8.25 | -6.29 | -5.83 | - |
| Diluted Shares Outstanding | 42.45M | 49.78M | 56.58M | 60.85M | 67.8M | 69.91M | 73.54M | 90.54M | 98.6M | 100.6M |
| Basic Shares Outstanding | 42.45M | 49.78M | 56.58M | 60.85M | 67.8M | 69.91M | 73.54M | 90.54M | 98.6M | 100.6M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
RARE Balance Sheet
Ultragenyx Pharmaceutical Inc. (RARE) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 244.47M | 522.37M | 851.02M | 1.3B | 856.6M | 883.9M | 732.18M | 817.12M | 951M | 657M |
| Cash & Short-Term Investments | 244.47M | 459.71M | 755.23M | 1.2B | 740.2M | 747.76M | 577.21M | 610.02M | 693M | 413M |
| Cash Only | 100.49M | 113.43M | 433.58M | 713.53M | 307.58M | 132.94M | 213.58M | 173.73M | 434M | 175M |
| Short-Term Investments | 134M | 346.27M | 321.65M | 488.01M | 432.61M | 614.82M | 363.63M | 436.3M | 259M | 238M |
| Accounts Receivable | 5.17M | 12.74M | 32.84M | 23.09M | 28.43M | 40.45M | 73.39M | 121.8M | 159M | 121M |
| Days Sales Outstanding | 722.73 | 90.3 | 115.59 | 31.1 | 29.53 | 40.63 | 61.69 | 79.36 | 86.23 | 70.76 |
| Inventory | 757K | 7.07M | 11.55M | 13.05M | 16.23M | 26.77M | 33.97M | 45.01M | 52M | 55M |
| Days Inventory Outstanding | 276.31K | 2.25K | 467.84 | 777.05 | 370.08 | 344.97 | 274.25 | 214.1 | 174.13 | 170.65 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 68.93M | 47.62M | 40.29M | 47M | 68M |
| Total Non-Current Assets | 246.28M | 197.19M | 284.48M | 464.25M | 665.79M | 661.54M | 758.83M | 686.33M | 581M | 639M |
| Property, Plant & Equipment | 21.84M | 20.05M | 74.68M | 114.04M | 176.18M | 259.73M | 290.57M | 265.93M | 267M | 239M |
| Fixed Asset Turnover | 0.12x | 2.57x | 1.39x | 2.38x | 1.99x | 1.40x | 1.49x | 2.11x | 2.52x | 2.65x |
| Goodwill | 44.41M | 44.41M | 44.41M | 44.41M | 44.41M | 44.41M | 44.41M | 44.41M | 44M | 44M |
| Intangible Assets | 141.54M | 129.22M | 129M | 131.11M | 130.79M | 160.1M | 166.27M | 178.31M | 176M | 174M |
| Long-Term Investments | 9.97M | 1.82M | 32.93M | 165.88M | 293.86M | 148.97M | 199.9M | 135M | 59M | 132.52M |
| Other Non-Current Assets | 3.41M | 3.51M | 3.47M | 8.81M | 20.56M | 48.34M | 57.69M | 62.68M | 35M | 334.98M |
| Total Assets | 490.75M▲ 0% | 719.56M▲ 46.6% | 1.14B▲ 57.8% | 1.76B▲ 55.0% | 1.52B▼ 13.5% | 1.55B▲ 1.5% | 1.49B▼ 3.5% | 1.5B▲ 0.8% | 1.53B▲ 1.9% | 1.3B▲ 0% |
| Asset Turnover | 0.01x | 0.07x | 0.09x | 0.15x | 0.23x | 0.24x | 0.29x | 0.37x | 0.44x | 0.50x |
| Asset Growth % | -9.22% | 46.62% | 57.8% | 54.96% | -13.48% | 1.51% | -3.52% | 0.83% | 1.9% | -41.22% |
| Total Current Liabilities | 71.01M | 74.72M | 103.3M | 189.61M | 181.37M | 261.21M | 280.44M | 344.15M | 384M | 325M |
| Accounts Payable | 8.89M | 12.28M | 12.87M | 12.92M | 17.14M | 43.27M | 42.11M | 38.76M | 31M | 42M |
| Days Payables Outstanding | 1000K | 3.91K | 521.53 | 769.6 | 390.77 | 557.73 | 340.01 | 184.36 | 103.81 | 122.63 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 81M | 0 |
| Deferred Revenue (Current) | 5.99M | 0 | 0 | 59.22M | 7.61M | 1.48M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 142.79M | 87.47M | 183M | 283M |
| Current Ratio | 3.44x | 6.99x | 8.24x | 6.83x | 4.72x | 3.38x | 2.61x | 2.37x | 2.48x | 2.48x |
| Quick Ratio | 3.43x | 6.90x | 8.13x | 6.76x | 4.63x | 3.28x | 2.49x | 2.24x | 2.34x | 2.34x |
| Cash Conversion Cycle | -1000K | -1.57K | 61.9 | 38.54 | 8.85 | -172.13 | -4.07 | 109.09 | 156.55 | 118.78 |
| Total Non-Current Liabilities | 36.28M | 35.92M | 378.43M | 415.57M | 418.47M | 931.74M | 935.16M | 897.01M | 1.22B | 1.2B |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.17B | 0 |
| Capital Lease Obligations | 0 | 0 | 29.76M | 39.25M | 30.9M | 19.81M | 30.57M | 30.04M | 24M | 70.22M |
| Deferred Tax Liabilities | 31.17M | 31.17M | 33.31M | 33.31M | 33.31M | 31.67M | 0 | 30.06M | 30M | 120.12M |
| Other Non-Current Liabilities | 5.12M | 4.76M | 315.37M | 335.67M | 352.79M | 880.26M | 904.59M | 836.91M | -4M | 1.96B |
| Total Liabilities | 107.3M | 110.65M | 481.73M | 605.18M | 599.84M | 1.19B | 1.22B | 1.24B | 1.6B | 1.52B |
| Total Debt | 0 | 0 | 36.99M | 48.23M | 41.97M | 31.59M | 43.17M | 40.34M | 1.28B | 0 |
| Net Debt | -100.49M | -113.43M | -396.59M | -665.3M | -265.61M | -101.35M | -170.41M | -133.39M | 842M | -175M |
| Debt / Equity | - | - | 0.06x | 0.04x | 0.05x | 0.09x | 0.16x | 0.15x | - | -0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.33x |
| Interest Coverage | - | - | -350.93x | -4.57x | -14.40x | -15.31x | -8.22x | -8.00x | -8.63x | -14.49x |
| Total Equity | 383.45M▲ 0% | 608.91M▲ 58.8% | 653.76M▲ 7.4% | 1.15B▲ 76.6% | 922.56M▼ 20.1% | 352.49M▼ 61.8% | 275.41M▼ 21.9% | 262.3M▼ 4.8% | -73M▼ 127.8% | -229M▲ 0% |
| Equity Growth % | -19.1% | 58.8% | 7.37% | 76.57% | -20.08% | -61.79% | -21.87% | -4.76% | -127.83% | -538.07% |
| Book Value per Share | 9.03 | 12.23 | 11.56 | 18.97 | 13.61 | 5.04 | 3.74 | 2.90 | -0.74 | -2.28 |
| Total Shareholders' Equity | 383.45M | 608.91M | 653.76M | 1.15B | 922.56M | 352.49M | 275.41M | 255.3M | -80M | -236M |
| Common Stock | 44K | 51K | 58K | 67K | 69K | 70K | 82K | 92K | 0 | 0 |
| Retained Earnings | -832.67M | -1.03B | -1.43B | -1.62B | -2.07B | -2.78B | -3.39B | -3.96B | -4.53B | -4.72B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | -432K | -3.59M | -8M | 0 |
| Accumulated OCI | -5.68M | -633K | -147K | 689K | -1.4M | -6.57M | 647K | -643K | 9M | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7M | 7M | 7M |
RARE Cash Flow Statement
Ultragenyx Pharmaceutical Inc. (RARE) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -253.84M | -290.57M | -345.38M | -132.22M | -338.69M | -380.46M | -474.81M | -414.19M | -466M | -466M |
| Operating CF Margin % | -9718.34% | -564.26% | -333.01% | -48.78% | -96.38% | -104.72% | -109.34% | -73.93% | -69.24% | - |
| Operating CF Growth % | -57.69% | -14.47% | -18.87% | 61.72% | -156.16% | -12.33% | -24.8% | 12.77% | -12.51% | -121.05% |
| Net Income | -302.14M | -197.61M | -402.73M | -186.57M | -454.02M | -707.42M | -606.64M | -569.18M | -575M | -609.36M |
| Depreciation & Amortization | 5.83M | 19.54M | 8.54M | 12.26M | 13.24M | 18.22M | 26.01M | 35.54M | 0 | -4.16M |
| Stock-Based Compensation | 68.01M | 80.11M | 82M | 85.73M | 104.95M | 130.38M | 135.21M | 158.03M | 153M | 143.54M |
| Deferred Taxes | -16.25M | -167.65M | -18.94M | -169.78M | 48.67M | 0 | -1.62M | 0 | 0 | 0 |
| Other Non-Cash Items | 10.93M | -156K | 1.69M | 21.46M | 11.71M | 118.12M | -12.67M | -52.5M | -21M | -60.17M |
| Working Capital Changes | -20.23M | -24.79M | -15.94M | 104.66M | -63.24M | 60.23M | -15.1M | 13.92M | -23M | 33.63M |
| Change in Receivables | -5.17M | -7.58M | -20.1M | 9.84M | -5.43M | -12.07M | -22.78M | -33.6M | -31M | -22.06M |
| Change in Inventory | -757K | -5.28M | -4.45M | -1.35M | -3.12M | -9.7M | -6.93M | -11.21M | -6M | -9.24M |
| Change in Payables | 3.46M | 3.37M | 20.65M | 29.6M | 2.81M | 79.84M | 2.38M | 46.99M | 24M | 15.45M |
| Cash from Investing | 56.42M | -33.33M | -13.04M | -179.12M | -195.37M | -291.65M | 168M | -17.77M | 236M | 67.11M |
| Capital Expenditures | -2.79M | -4.08M | -24.83M | -43.91M | -73.09M | -116.12M | -44.27M | -7.49M | 0 | -4.74M |
| CapEx % of Revenue | 106.93% | 7.92% | 23.94% | 16.2% | 20.8% | 31.96% | 10.19% | 1.34% | 0.89% | - |
| Acquisitions | -142.8M | 0 | -11.79M | 0 | 0 | -75.03M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 934K | 170.32M | 11.79M | -5.55M | -942K | -30.84M | -7.55M | -14.94M | 236M | 40.91M |
| Cash from Financing | 136.27M | 336.85M | 679.31M | 600.27M | 118.55M | 501.21M | 388.14M | 399.24M | 478M | 477.84M |
| Debt Issued (Net) | -4.94M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 392M | 392M |
| Equity Issued (Net) | 131.96M | 309.02M | 355.24M | 511.21M | 78.94M | 0 | 379.75M | 380.98M | 86M | 85.84M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 9.25M | 27.83M | 324.06M | 89.06M | 39.61M | 501.21M | 8.39M | 18.26M | 0 | 0 |
| Net Change in Cash | -60.63M▲ 0% | 12.48M▲ 120.6% | 320.72M▲ 2469.0% | 290.05M▼ 9.6% | -416.71M▼ 243.7% | -171.98M▲ 58.7% | 81.8M▲ 147.6% | -35.24M▼ 143.1% | 253.47M▲ 819.3% | 50.18M▲ 0% |
| Free Cash Flow | -256.64M▲ 0% | -294.64M▼ 14.8% | -370.21M▼ 25.6% | -176.13M▲ 52.4% | -411.79M▼ 133.8% | -526.59M▼ 27.9% | -521.57M▲ 1.0% | -421.68M▲ 19.2% | -472M▼ 11.9% | -487.2M▲ 0% |
| FCF Margin % | -9825.27% | -572.18% | -356.96% | -64.98% | -117.18% | -144.93% | -120.11% | -75.27% | -70.13% | -72.78% |
| FCF Growth % | -49.94% | -14.81% | -25.65% | 52.43% | -133.8% | -27.88% | 0.95% | 19.15% | -11.93% | -17.95% |
| FCF per Share | -6.05 | -5.92 | -6.54 | -2.89 | -6.07 | -7.53 | -7.09 | -4.66 | -4.79 | -4.79 |
| FCF Conversion (FCF/Net Income) | 0.84x | 1.47x | 0.86x | 0.71x | 0.75x | 0.54x | 0.78x | 0.73x | 0.81x | 0.80x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RARE Key Ratios
Ultragenyx Pharmaceutical Inc. (RARE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -70.48% | -39.83% | -63.79% | -20.64% | -43.72% | -110.96% | -193.23% | -211.71% | -607.51% | 1910.91% |
| Return on Invested Capital (ROIC) | -82.81% | -71.56% | -84.54% | -66.36% | -49.96% | -107.19% | -239.74% | -343.71% | -89.37% | -89.37% |
| Gross Margin | 99.96% | 97.77% | 91.31% | 97.74% | 95.44% | 92.21% | 89.59% | 86.3% | 83.8% | 83.57% |
| Net Margin | -11567.34% | -383.75% | -388.31% | -68.84% | -129.2% | -194.71% | -139.7% | -101.6% | -85.44% | -91.03% |
| Debt / Equity | - | - | 0.06x | 0.04x | 0.05x | 0.09x | 0.16x | 0.15x | - | -0.00x |
| Interest Coverage | - | - | -350.93x | -4.57x | -14.40x | -15.31x | -8.22x | -8.00x | -8.63x | -14.49x |
| FCF Conversion | 0.84x | 1.47x | 0.86x | 0.71x | 0.75x | 0.54x | 0.78x | 0.73x | 0.81x | 0.80x |
| Revenue Growth | 1863.91% | 1871.48% | 101.41% | 161.32% | 29.66% | 3.39% | 19.52% | 29.01% | 20.13% | 13.33% |
RARE SEC Filings & Documents
Ultragenyx Pharmaceutical Inc. (RARE) SEC filings — annual & quarterly reports (10-K, 10-Q)
RARE Frequently Asked Questions
Ultragenyx Pharmaceutical Inc. (RARE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Ultragenyx Pharmaceutical Inc. (RARE) reported $669.4M in revenue for fiscal year 2025.
Ultragenyx Pharmaceutical Inc. (RARE) grew revenue by 20.1% over the past year. This is strong growth.
Ultragenyx Pharmaceutical Inc. (RARE) reported a net loss of $609.4M for fiscal year 2025.
Dividend & Returns
Ultragenyx Pharmaceutical Inc. (RARE) has a return on equity (ROE) of -607.5%. Negative ROE indicates the company is unprofitable.
Ultragenyx Pharmaceutical Inc. (RARE) had negative free cash flow of $487.2M in fiscal year 2025, likely due to heavy capital investments.
Explore More RARE
Ultragenyx Pharmaceutical Inc. (RARE) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates